Filing Flows › Tarsus Pharmaceuticals (TARS) › Q1 2025
Tarsus Pharmaceuticals (TARS) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 1, 2025
Tarsus Pharmaceuticals (TARS) reported revenue of $78.3M for the first quarter 2025 (Q1 2025), +184% from a year earlier and +18% from the quarter before. Operating margin was -33.5%, net loss $25.1M (32.1% of revenue).
Tarsus Pharmaceuticals, Q1 2025: revenue $78.3M (+184% year over year), operating margin -33.5%, net loss $25.1M, operating cash flow −$20.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $78.3M | +18% | +184% |
| Operating profit | −$26.3M | — | — |
| Net earnings | −$25.1M | — | — |
| Operating cash flow | −$20.7M | — | — |
What changed
Revenue was $78.3M in Q1 2025, up 184% year over year and up 18% from the previous quarter.
Operating costs exceeded revenue by $26.3M, an operating margin of -33.5%. Total costs grew 60% against revenue growth of 184%. The fastest-growing cost line was SG&A (+65%). The quarter ended with a net loss of $25.1M, wider than the previous quarter's $23.1M loss.
Operating cash flow was −$20.7M. Non-cash charges added back $460K of depreciation and amortization and $6.9M of share-based compensation. Working capital and other items used $2.9M. Capital expenditures of $590K exceeded it, leaving free cash flow of −$21.2M.
Questions
What was Tarsus Pharmaceuticals' revenue in the first quarter 2025?
Tarsus Pharmaceuticals (TARS) reported revenue of $78.3M for the first quarter 2025 (Q1 2025), +184% from a year earlier and +18% from the quarter before.
Was Tarsus Pharmaceuticals profitable in the first quarter 2025?
Operating loss was $26.3M (-33.5% of revenue) and net loss $25.1M.